EUnetHTA Joint Assessment

Just as a reminder from one of our previous posts, the opportunity for open patient input in one of EUnetHTA’s joint assessment on patients using the new drug brolucizumab for treatment of neovascular age-related macular degeneration, or wet AMD, is coming to a close. The chance to contribute to this opportunity closes on July 15th, 13:00PM CEST. Follow the link below to contribute!

 

https://www.eunethta.eu/amd/

Newsletter

To keep up to date with our news and activities,
please leave your details below

Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.